metricas
covid
Buscar en
Annals of Hepatology
Toda la web
Inicio Annals of Hepatology The role of cirrhosis etiology in the development of acute kidney injury and dea...
Journal Information
Vol. 29. Issue S2.
Abstracts Asociación Mexicana del Hígado (AMH) 2023
(February 2024)
Share
Share
Download PDF
More article options
Vol. 29. Issue S2.
Abstracts Asociación Mexicana del Hígado (AMH) 2023
(February 2024)
Full text access
The role of cirrhosis etiology in the development of acute kidney injury and death
Visits
167
Cristian Y. Sánchez-Sánchez1, Karina Cazarin-Chávez1, Diego F. Abendaño-Rivera1, María F. Higuera-De La Tijera1, Daniel Santana-Vargas2, José L. Pérez-Hernández1
1 Department of Gastroenterology and Hepatology General Hospital of Mexico “Dr. Eduardo Liceaga", Mexico City, Mexico
2 Research Department General Hospital of Mexico “Dr. Eduardo Liceaga", Mexico City, Mexico
This item has received
Article information
Abstract
Full Text
Download PDF
Statistics
Figures (2)
Special issue
This article is part of special issue:
Vol. 29. Issue S2

Abstracts Asociación Mexicana del Hígado (AMH) 2023

More info
Introduction and Objectives

: Patients with hepatic cirrhosis (HC) are at risk of developing acute kidney injury (AKI) due to multiple factors. The main types of AKI are hypovolemia, acute tubular necrosis (ATN), and urinary obstruction. Common causes of HC include MAFLD, alcohol consumption, viral and autoimmune diseases, which may have a different role in the risk for AKI and mortality. This study aims to assess the etiology of cirrhosis in the development of acute kidney injury (AKI) and mortality.

Materials and Patients

Retrospective, analytical, observational study of patients with CH, analyzing etiology, type of AKI, and mortality. Statistical analysis: Using the Log-Rank test, the Kaplan-Meier curve was performed considering death at 28 and 90 days to assess the mortality rate associated with etiology. The Chi-square test with Bonferroni correction was conducted to evaluate the association between etiology and type of AKI; a significance level of ≤ 0.05 was considered.

Results

A total of 201 patients with CH were included, 106 of them being male (52.73%), with an average age of 55 ± 10.4 years. Child-Pugh classification distribution was as follows: A: 25 (12.43%), B: 70 (34.82%), and C: 106 (52.73%). The average MELD-Na score was 21.8 ± 9.45 points. The cumulative mortality rate at 28 days was 18.4% (37); the comparison by etiology showed statistical significance with a Chi-square test of 13.23 (4), p=0.01. The mean survival for MAFLD was 27.7, alcohol-related was 23.8, autoimmune was 24.1, viral was 25.92, and dual etiology was 22.56, with an overall survival of 24.88. The comparison at 90 days was significant, with a Chi-square test of 10.46 (4), p=0.033, and a cumulative mortality rate of 24.4% (49). The mean survival for MAFLD was 86.82, alcohol-related was 70.02, autoimmune was 67.03, viral was 80.07, dual etiology was 66.56, and the overall survival was 74.84. Association tests between etiology and type of renal injury showed statistical significance, with a Chi-square test of 29.65 (8), p=<0.001. Differences were found between the alcohol-hypovolemic group and the non-renal injury and ATN groups.

Conclusions

Dual etiology and autoimmune factors confer higher mortality at 28 and 90 days, respectively, while alcohol consumption increases the risk of AKI due to hypovolemia.

Full Text

Ethical statement

The protocol was registered and approved by the Ethics Committee. The identity of the patients is protected. Consentment was obtained.

Declaration of interests

None

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Figure 1. 28-day survival by etiology of Hepatic Cirrhosis.

Figure 2. 90-day survival by etiology of Hepatic Cirrhosis.

Download PDF
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

Quizás le interese:
10.1016/j.aohep.2024.101435
No mostrar más